# BRIEF R&D CURRICULUM VITAE Mr Ansar Mahmood

# Name:

Mr Ansar Mahmood

# **Present appointment:**

Appointed Consultant in Trauma & Orthopaedics – University Hospitals Birmingham 2015 I remain in full time NHS service and I am clinically active.

Co-ordinating Trauma Consultant, Major Trauma Service (MTS) – UHB

#### Address:

# **Queen Elizabeth Hospital Birmingham**

Room 21H, 6th Floor Nuffield House

Trauma & Orthopaedics - University Hospitals Birmingham NHS Foundation Trust Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston Birmingham, B15 2GW

Telephone number:	Email address:
0121 371 4946	Ansar.Mahmood@uhb.nhs.uk

# **Qualifications:**

MB, CHB, MRCS Ed, FRCS (T&O)

# **Professional registration:**

GMC 4764056 - active

# **Previous and other appointments:**

President to the British Trauma Society – (Current)

Research Lead for Orthopaedic Trauma & The Major Trauma Service - UHB (Current)

Surgical Advisor to the National Wound-Care Strategy Board – UK (Current)

Senior Trauma Fellow – Oxford Trauma Unit, John Radcliffe Hospital, Oxford – Feb -Sept '16

Post CCT - Trauma and Knee Unit at Aintree University Hospital – Aug 2015 – Feb 2016

Specialty Registrar in Trauma & Orthopaedics, Mersey deanery – Aug 2007- Aug 2015 (CCT)

Research & Publication Experience:		
PI at UHB in the following studies:		
- WHiTE Cohort		
- WHiTE-10 LIT Trial		
- WHiTE-8- Closed 21 data finalised		
- Cryostatt-2		
- National REBOA Trial		
- ORiF – Rib Fracture Trial		
- FAME Trial		
3 NIHR Portfolio trials in set up and 2 x commercial trial in set up.  Co-PI applicant on NIHR130632: ERASER TRIAL: Early Rib Analgesia with Serratus. A  Pragmatic Randomised Control Trial evaluating the clinical and cost-effectiveness of  Serratus Anterior Plane Block with catheter insertion compared to Usual Care in patients  with multiple rib fractures. Successfully funded for 1.5M in 2020.		
Research training:		
GCP update – May 2022		
Principal Investigator Masterclass – May 2017 (UHB R&D Department)		

Signature:	Date:
A	30.06.2022